Andrew Kung

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6745950/publications.pdf

Version: 2024-02-01

334 papers	41,421 citations	2426 97 h-index	2446 197 g-index
345 all docs	345 docs citations	345 times ranked	52046 citing authors

#	Article	IF	Citations
1	Selective inhibition of BET bromodomains. Nature, 2010, 468, 1067-1073.	13.7	3,456
2	BET Bromodomain Inhibition asÂa Therapeutic Strategy to Target c-Myc. Cell, 2011, 146, 904-917.	13.5	2,432
3	Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005, 7, 129-141.	7.7	1,387
4	Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix. Science, 2004, 305, 1466-1470.	6.0	1,236
5	Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes and Development, 2005, 19, 489-501.	2.7	1,122
6	Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor. Cancer Cell, 2011, 20, 53-65.	7.7	842
7	MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L. Cancer Cell, 2011, 20, 66-78.	7.7	791
8	Role of T-bet in Commitment of TH1 Cells Before IL-12-Dependent Selection. Science, 2001, 292, 1907-1910.	6.0	730
9	Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature Medicine, 2000, 6, 1335-1340.	15.2	726
10	Direct inhibition of the NOTCH transcription factor complex. Nature, 2009, 462, 182-188.	13.7	712
11	Oncogenic BRAF Regulates Oxidative Metabolism via PGC1Î± and MITF. Cancer Cell, 2013, 23, 302-315.	7.7	689
12	Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. Cancer Cell, 2013, 24, 777-790.	7.7	635
13	A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13513-13518.	3.3	590
14	Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell, 2004, 5, 221-230.	7.7	579
15	SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature, 2011, 471, 104-109.	13.7	558
16	Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery, 2013, 3, 308-323.	7.7	549
17	Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood, 2012, 119, 2579-2589.	0.6	544
18	NF-Î²B Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis. Molecular Cell, 2014, 56, 219-231.	4.5	507

#	Article	IF	Citations
19	H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias. Cancer Cell, 2008, 14, 355-368.	7.7	494
20	Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell, 2004, 6, 33-43.	7.7	458
21	Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300. Science, 2003, 300, 342-344.	6.0	431
22	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature, 2012, 483, 613-617.	13.7	430
23	Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)â€“dependent migration and homing in multiple myeloma. Blood, 2007, 109, 2708-2717.	0.6	413
24	Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1Â. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 5367-5372.	3.3	403
25	CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood, 2009, 113, 4341-4351.	0.6	398
26	A HIF1Î± Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. PLoS Genetics, 2005, 1, e8.	1.5	394
27	Inhibition of FLT3 in MLL. Cancer Cell, 2003, 3, 173-183.	7.7	389
28	p300/MDM2 Complexes Participate in MDM2-Mediated p53 Degradation. Molecular Cell, 1998, 2, 405-415.	4.5	383
29	Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4260-4265.	3.3	366
30	Novel antiâ€“B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood, 2014, 123, 3128-3138.	0.6	361
31	Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes and Development, 2000, 14, 272-277.	2.7	359
32	Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes and Development, 1999, 13, 64-75.	2.7	349
33	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature Genetics, 2014, 46, 364-370.	9.4	333
34	BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood, 2012, 120, 2843-2852.	0.6	329
35	Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. Journal of the National Cancer Institute, 2009, 101, 519-532.	3.0	328
36	Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes and Development, 2000, 14, 272-7.	2.7	326

#	Article	IF	Citations
37	Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature, 2015, 526, 273-276.	13.7	307
38	Lipocalin 2 promotes breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3913-3918.	3.3	302
39	Examining the utility of patient-derived xenograft mouse models. Nature Reviews Cancer, 2015, 15, 311-316.	12.8	300
40	HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood, 2009, 113, 2375-2385.	0.6	292
41	The Requirement for Cyclin D Function in Tumor Maintenance. Cancer Cell, 2012, 22, 438-451.	7.7	284
42	Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nature Medicine, 2010, 16, 483-489.	15.2	281
43	Antimyeloma activity of heat shock protein-90 inhibition. Blood, 2005, 107, 1092-1100.	0.6	278
44	Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood, 2012, 119, 5782-5794.	0.6	268
45	A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53. Cancer Cell, 2010, 18, 411-422.	7.7	264
46	CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia, 2014, 28, 155-165.	3.3	250
47	High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nature Biotechnology, 2016, 34, 419-423.	9.4	245
48	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	7.7	227
49	Targeted Disruption of the BCL9/Î²-Catenin Complex Inhibits Oncogenic Wnt Signaling. Science Translational Medicine, 2012, 4, 148ra117.	5.8	214
50	Cell line-specific differences in the control of cell cycle progression in the absence of mitosis.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 9553-9557.	3.3	212
51	Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nature Biotechnology, 2009, 27, 77-83.	9.4	210
52	An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells. Cancer Cell, 2010, 17, 298-310.	7.7	207
53	Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 14789-14794.	3.3	203
54	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood, 2019, 134, 2361-2368.	0.6	190

#	Article	IF	Citations
55	Structural basis for negative regulation of hypoxia-inducible factor-1Î± by CITED2. Nature Structural and Molecular Biology, 2003, 10, 504-512.	3.6	188
56	Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming. Cancer Research, 2011, 71, 2686-2696.	0.4	182
57	Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene. Cancer Research, 2010, 70, 9827-9836.	0.4	181
58	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nature Medicine, 2015, 21, 1182-1189.	15.2	180
59	Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma. Cancer Cell, 2012, 22, 359-372.	7.7	179
60	Efficacy of BET Bromodomain Inhibition in Kras-Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 6183-6192.	3.2	179
61	Oncogenic MITF dysregulation in clear cell sarcoma: Defining the MiT family of human cancers. Cancer Cell, 2006, 9, 473-484.	7.7	172
62	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nature Communications, 2014, 5, 3469.	5.8	171
63	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nature Genetics, 2018, 50, 979-989.	9.4	168
64	Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia, 2013, 27, 66-74.	3.3	166
65	Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia, 2013, 27, 852-860.	3.3	165
66	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nature Medicine, 2012, 18, 1118-1122.	15.2	162
67	Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency. Cancer Cell, 2012, 21, 547-562.	7.7	158
68	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. Journal of Experimental Medicine, 2011, 208, 1809-1822.	4.2	153
69	A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. Journal of Clinical Investigation, 2012, 122, 2018-2031.	3.9	153
70	COVID-19 in Children With Cancer in New York City. JAMA Oncology, 2020, 6, 1459.	3.4	152
71	<scp>KPT</scp>â€330 inhibitor of <scp>CRM</scp>1 (<scp>XPO</scp>1)â€mediated nuclear export has selective antiâ€leukaemic activity in preclinical models of <scp>T</scp>â€cell acute lymphoblastic leukaemia and acute myeloid leukaemia. British Journal of Haematology, 2013, 161, 117-127.	1.2	149
72	A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells. Cancer Cell, 2013, 24, 182-196.	7.7	147

#	Article	IF	Citations
73	Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Medicine, 2016, 8, 133.	3.6	147
74	Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. Journal of Experimental Medicine, 2012, 209, 259-273.	4.2	146
75	CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16275-16280.	3.3	140
76	Proteomic and Genetic Approaches Identify Syk as an AML Target. Cancer Cell, 2009, 16, 281-294.	7.7	140
77	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 232-237.	3.3	136
78	An expanded universe of cancer targets. Cell, 2021, 184, 1142-1155.	13.5	135
79	Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. Genome Biology, 2009, 10, R113.	13.9	131
80	Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer. Cancer Cell, 2013, 23, 390-405.	7.7	130
81	Mouse Reporter Strain for Noninvasive Bioluminescent Imaging of Cells that Have Undergone Cre-Mediated Recombination. Molecular Imaging, 2003, 2, 297-302.	0.7	129
82	HIF2Î± cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation, 2009, 119, 2160-2170.	3.9	129
83	Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma. PLoS Medicine, 2007, 4, e122.	3.9	129
84	Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nature Medicine, 2013, 19, 1518-1523.	15.2	127
85	Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer. Cancer Discovery, 2013, 3, 870-879.	7.7	127
86	SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 226-242.	7.7	126
87	CXCR4 Inhibition Synergizes with Cytotoxic Chemotherapy in Gliomas. Clinical Cancer Research, 2006, 12, 6765-6771.	3.2	119
88	Targeting MTHFD2 in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 1285-1306.	4.2	118
89	Recurrent EML4â€“NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Modern Pathology, 2018, 31, 463-473.	2.9	117
90	Noninvasive Bioluminescence Imaging of Luciferase Expressing Intracranial U87 Xenografts: Correlation with Magnetic Resonance Imaging Determined Tumor Volume and Longitudinal Use in Assessing Tumor Growth and Antiangiogenic Treatment Effect. Neurosurgery, 2006, 58, 365-372.	0.6	112

#	Article	IF	Citations
91	Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro-Oncology, 2009, 11, 109-121.	0.6	111
92	Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB Journal, 2006, 20, 947-949.	0.2	109
93	Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia, 2012, 26, 985-990.	3.3	107
94	Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell and Melanoma Research, 2008, 21, 457-463.	1.5	104
95	Cytotoxic effects of cell cycle phase specific agents: result of cell cycle perturbation. Cancer Research, 1990, 50, 7307-17.	0.4	104
96	P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood, 2012, 119, 1468-1478.	0.6	103
97	MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia, 2008, 22, 66-77.	3.3	102
98	Antiproliferative Effects of CDK4/6 Inhibition inCDK4-Amplified Human LiposarcomaIn VitroandIn Vivo. Molecular Cancer Therapeutics, 2014, 13, 2184-2193.	1.9	102
99	Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E924-33.	3.3	101
100	Widespread CXCR4 Activation in Astrocytomas Revealed by Phospho-CXCR4-Specific Antibodies. Cancer Research, 2005, 65, 11392-11399.	0.4	100
101	Prosurvival and Prodeath Effects of Hypoxia-inducible Factor-1Î± Stabilization in a Murine Hippocampal Cell Line. Journal of Biological Chemistry, 2005, 280, 3996-4003.	1.6	98
102	Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood, 2007, 109, 2112-2120.	0.6	98
103	A Class of Human Proteins that Deliver Functional Proteins into Mammalian Cells InÂVitro and InÂVivo. Chemistry and Biology, 2011, 18, 833-838.	6.2	98
104	The intersection of genetic and chemical genomic screens identifies GSK-3Î± as a target in human acute myeloid leukemia. Journal of Clinical Investigation, 2012, 122, 935-947.	3.9	96
105	In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor N-acetylleucylleucylnorleucinal.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 3353-3357.	3.3	94
106	Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity. Gastroenterology, 2006, 131, 1734-1742.	0.6	93
107	p300 Interacts with the Nuclear Proto-Oncoprotein SYT as Part of the Active Control of Cell Adhesion. Cell, 2000, 102, 839-848.	13.5	92
108	Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation. Chemistry and Biology, 2013, 20, 713-725.	6.2	89

#	Article	IF	Citations
109	Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2017, 23, 1012-1024.	3.2	88
110	Anti-Apoptosis Mechanisms in Malignant Gliomas. Journal of Clinical Oncology, 2008, 26, 493-500.	0.8	87
111	Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9751-9756.	3.3	87
112	Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia, 2010, 24, 2100-2109.	3.3	87
113	The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes and Cancer, 2012, 3, 503-511.	0.6	87
114	Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. Journal of Clinical Investigation, 2008, 118, 3109-3122.	3.9	85
115	Cyclin D1 Represses p300 Transactivation through a Cyclin-dependent Kinase-independent Mechanism. Journal of Biological Chemistry, 2005, 280, 29728-29742.	1.6	82
116	Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABLâ€“ and mutant FLT3-expressing cells. Blood, 2008, 111, 3723-3734.	0.6	81
117	Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis inÂvivo. Fertility and Sterility, 2011, 96, 1021-1028.e1.	0.5	81
118	Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Molecular Cancer Therapeutics, 2007, 6, 1951-1961.	1.9	78
119	A Novel Noninvasive Model of Endometriosis for Monitoring the Efficacy of Antiangiogenic Therapy. American Journal of Pathology, 2006, 168, 2074-2084.	1.9	76
120	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	5.7	74
121	Therapeutic targeting of apoptosis pathways in cancer. Current Opinion in Oncology, 2008, 20, 97-103.	1.1	73
122	Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia, 2016, 30, 0-0.	3.3	72
123	New cast for a new era: preclinical cancer drug development revisited. Journal of Clinical Investigation, 2013, 123, 3639-3645.	3.9	72
124	Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget, 2014, 5, 8737-8749.	0.8	72
125	InÂVivo Imaging of Inflammatory Phagocytes. Chemistry and Biology, 2012, 19, 1199-1209.	6.2	70
126	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes and Development, 2014, 28, 479-490.	2.7	70

#	Article	IF	Citations
127	Exploiting an Asp-Glu â€œswitchâ€•in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Science Translational Medicine, 2018, 10, .	5.8	69
128	Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Molecular Cancer Therapeutics, 2008, 7, 1121-1129.	1.9	65
129	BET bromodomain proteins regulate enhancer function during adipogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2144-2149.	3.3	65
130	Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia, 2012, 26, 2233-2244.	3.3	64
131	Practices and Pitfalls of Mouse Cancer Models in Drug Discovery. Advances in Cancer Research, 2006, 96, 191-212.	1.9	62
132	Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRÎ±, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood, 2010, 115, 4206-4216.	0.6	61
133	Cyclin B1 Expression in HeLa S3 Cells Studied by Flow Cytometry. Experimental Cell Research, 1994, 211, 275-281.	1.2	59
134	Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Nonâ€“Small Cell Lung Cancer and Predict Strategies to Overcome Resistance. Clinical Cancer Research, 2014, 20, 1204-1211.	3.2	57
135	Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer. Molecular Cancer Therapeutics, 2014, 13, 1929-1941.	1.9	57
136	Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clinical Cancer Research, 2015, 21, 2348-2358.	3.2	57
137	Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro-Oncology, 2015, 17, 697-707.	0.6	57
138	A New Spectrin, Î²IV, Has a Major Truncated Isoform That Associates with Promyelocytic Leukemia Protein Nuclear Bodies and the Nuclear Matrix. Journal of Biological Chemistry, 2001, 276, 23974-23985.	1.6	55
139	Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. Molecular Cancer Therapeutics, 2017, 16, 1779-1790.	1.9	55
140	A stimulus-specific role for CREB-binding protein (CBP) in T cell receptor-activated tumor necrosis factor alpha gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3925-3929.	3.3	54
141	p53 Targets Simian Virus 40 Large T Antigen for Acetylation by CBP. Journal of Virology, 2004, 78, 8245-8253.	1.5	51
142	Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma. Molecular Cancer Therapeutics, 2012, 11, 942-951.	1.9	49
143	High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma. Cancer Research, 2013, 73, 2873-2883.	0.4	49
144	STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma. Cancer Cell, 2021, 39, 827-844.e10.	7.7	49

#	Article	IF	Citations
145	Targeting the AIB1 Oncogene through Mammalian Target of Rapamycin Inhibition in the Mammary Gland. Cancer Research, 2006, 66, 11381-11388.	0.4	48
146	Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors. Science Translational Medicine, 2017, 9, .	5.8	48
147	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the Î³-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Journal of Physical Education and Sports Management, 2015, 1, a000539.	0.5	47
148	In vivo Assessment of RAS-Dependent Maintenance of Tumor Angiogenesis by Real-time Magnetic Resonance Imaging. Cancer Research, 2005, 65, 8324-8330.	0.4	46
149	Glioblastoma Inhibition by Cell Surface Immunoglobulin Protein EWI-2, In Vitro and In Vivo. Neoplasia, 2009, 11, 77-IN10.	2.3	46
150	AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/Î²-catenin signaling pathway. Blood, 2013, 121, 4906-4916.	0.6	45
151	Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation. Human Molecular Genetics, 2008, 17, 1774-1782.	1.4	44
152	Allogeneic Hematopoietic Cell Transplantation for Children with Sickle Cell Disease Is Beneficial and Cost-Effective: A Single-Center Analysis. Biology of Blood and Marrow Transplantation, 2015, 21, 1258-1265.	2.0	43
153	Inhibition of Inflammatory Arthritis Using Fullerene Nanomaterials. PLoS ONE, 2015, 10, e0126290.	1.1	42
154	Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. Angiogenesis, 2013, 16, 541-551.	3.7	41
155	In Vivo Pharmacodynamic Imaging of Proteasome Inhibition. Molecular Imaging, 2009, 8, 7290.2009.00007.	0.7	40
156	Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. Blood, 2011, 118, 69-79.	0.6	40
157	Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. Journal of Biomedical Optics, 2011, 16, 011006.	1.4	39
158	Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Journal of Physical Education and Sports Management, 2015, 1, a000471.	0.5	39
159	Identification of AML1-ETO modulators by chemical genomics. Blood, 2009, 113, 6193-6205.	0.6	38
160	Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1646-1653.	2.0	37
161	Mouse Reporter Strain for Noninvasive Bioluminescent Imaging of Cells that have Undergone Cre-Mediated Recombination. Molecular Imaging, 2003, 2, 153535002003031.	0.7	36
162	The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia, 2012, 26, 481-489.	3.3	34

#	Article	IF	Citations
163	Germline SDHA mutations in children and adults with cancer. Journal of Physical Education and Sports Management, 2018, 4, a002584.	0.5	33
164	In vivo pharmacodynamic imaging of proteasome inhibition. Molecular Imaging, 2009, 8, 140-7.	0.7	33
165	Systematic in vivo structure-function analysis of p300 in hematopoiesis. Blood, 2009, 114, 4804-4812.	0.6	32
166	Acute Gastrointestinal Graft-vs-Host Disease Is Associated With Increased Enteric Bacterial Bloodstream Infection Density in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2015, 61, 350-357.	2.9	32
167	A recurrent novel MGAâ€“NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcoma. Journal of Physical Education and Sports Management, 2018, 4, a003194.	0.5	32
168	Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma. JCO Precision Oncology, 2017, 2017, 1-8.	1.5	31
169	BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene, 2020, 39, 2305-2327.	2.6	31
170	Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. Nature Communications, 2022, 13, 2485.	5.8	31
171	Leukemia-specific delivery of mutant NOTCH1 targeted therapy. Journal of Experimental Medicine, 2018, 215, 197-216.	4.2	30
172	High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma. Clinical Cancer Research, 2019, 25, 4552-4566.	3.2	30
173	Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood, 2008, 112, 5161-5170.	0.6	29
174	Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. Journal of Neuro-Oncology, 2011, 104, 179-189.	1.4	29
175	A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. Neuro-Oncology, 2011, 13, 820-829.	0.6	29
176	Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience. Frontiers in Pediatrics, 2017, 5, 265.	0.9	29
177	Mice heterozygous for CREB binding protein are hypersensitive to Î³-radiation and invariably develop myelodysplastic/myeloproliferative neoplasm. Experimental Hematology, 2012, 40, 295-306.e5.	0.2	28
178	Noninvasive Imaging of Tumor Burden and Molecular Pathways in Mouse Models of Cancer. Cold Spring Harbor Protocols, 2015, 2015, pdb.top069930.	0.2	28
179	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor â€“ Microenvironment Interactions.. Blood, 2010, 116, 1574-1574.	0.6	28
180	Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation. PLoS ONE, 2011, 6, e20226.	1.1	27

#	Article	IF	Citations
181	Overcoming challenges to meaningful informed consent for whole genome sequencing in pediatric cancer research. Pediatric Blood and Cancer, 2015, 62, 1374-1380.	0.8	27
182	Anti-inflammatory properties of histone deacetylase inhibitors. Journal of Trauma, 2012, 72, 347-354.	2.3	26
183	Shikonin, a natural product from the root of Lithospermum erythrorhizon, is a cytotoxic DNA-binding agent. European Journal of Pharmaceutical Sciences, 2013, 49, 18-26.	1.9	26
184	Isabl Platform, a digital biobank for processing multimodal patient data. BMC Bioinformatics, 2020, 21, 549.	1.2	26
185	Incongruity of Imaging Using Fluorescent 2-DG Conjugates Compared to 18F-FDG in Preclinical Cancer Models. Molecular Imaging and Biology, 2012, 14, 553-560.	1.3	25
186	A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma. Journal of Physical Education and Sports Management, 2017, 3, a001396.	0.5	25
187	Targeted Imaging of Ewing Sarcoma in Preclinical Models Using a 64Cu-Labeled Anti-CD99 Antibody. Clinical Cancer Research, 2014, 20, 678-687.	3.2	23
188	Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood, 2015, 125, 3133-3143.	0.6	23
189	Bacterial bloodstream infections in pediatric allogeneic hematopoietic stem cell recipients before and after implementation of a central line-associated bloodstream infection protocol: A single-center experience. American Journal of Infection Control, 2016, 44, 1650-1655.	1.1	23
190	HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget, 2017, 8, 80109-80123.	0.8	23
191	11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. Cancer, 2020, 126, 3114-3121.	2.0	23
192	Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood. Bone Marrow Transplantation, 2004, 34, 795-798.	1.3	21
193	Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases. Pediatric Transplantation, 2014, 18, 211-216.	0.5	21
194	Targeting oncogenic interleukinâ€7 receptor signalling with Nâ€acetylcysteine in T cell acute lymphoblastic leukaemia. British Journal of Haematology, 2015, 168, 230-238.	1.2	20
195	In vivo imaging of endogenous enzyme activities using luminescent 1,2-dioxetane compounds. Journal of Biomedical Science, 2015, 22, 45.	2.6	20
196	BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1Î± activation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9600-E9609.	3.3	20
197	Adipocytes sensitize melanoma cells to environmental TGF-Î² cues by repressing the expression of miR-211. Science Signaling, 2019, 12, .	1.6	20
198	Pediatric Sarcoma Data Forms a Unique Cluster Measured via the Earth Moverâ€™s Distance. Scientific Reports, 2017, 7, 7035.	1.6	19

#	Article	IF	Citations
199	cDNA expression cloning in human cells using the pÎ»DR2 episomal vector system. Methods, 1992, 4, 111-131.	1.9	18
200	Desferroxamine infusion increases cerebral blood flow: a potential association with hypoxia-inducible factor-1. Clinical Science, 2009, 116, 771-779.	1.8	18
201	Efficacy of Tacrolimus/Mycophenolate Mofetil as Acute Graft-Versus-Host Disease Prophylaxis and the Impact of Subtherapeutic Tacrolimus Levels in Children after Matched Sibling Donor Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 496-502.	2.0	17
202	Germline BRCA2 mutations detected in pediatric sequencing studies impact parentsâ€™ evaluation and care. Journal of Physical Education and Sports Management, 2017, 3, a001925.	0.5	17
203	In Vivo Mobilization of Multiple Myeloma Cells Out of the Bone Marrow Using the CXCR4 Inhibitor AMD3100 and Bortezomib: Implications for Sensitization of Myeloma Cells to Apoptosis.. Blood, 2007, 110, 2501-2501.	0.6	16
204	Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia, 2010, 24, 1375-1378.	3.3	15
205	Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors. Molecular Cancer Therapeutics, 2010, 9, 2468-2477.	1.9	15
206	A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Medicine, 2016, 8, 116.	3.6	15
207	Image-guided transplantation of single cells in the bone marrow of live animals. Scientific Reports, 2017, 7, 3875.	1.6	15
208	The F-box Protein Î²-TrCp1/Fbw1a Interacts with p300 to Enhance Î²-Catenin Transcriptional Activity. Journal of Biological Chemistry, 2009, 284, 13033-13044.	1.6	14
209	In vivo Imaging Method to Distinguish Acute and Chronic Inflammation. Journal of Visualized Experiments, 2013, , .	0.2	14
210	Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-ÎºB Pathway in Preclinical Models of Pediatric High-Grade Glioma. Molecular Cancer Therapeutics, 2020, 19, 540-551.	1.9	14
211	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. Molecular Cancer Research, 2021, 19, 1146-1155.	1.5	14
212	Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 957-961.	2.0	13
213	Differential Disruption of EWS-FLI1 Binding by DNA-Binding Agents. PLoS ONE, 2013, 8, e69714.	1.1	12
214	Antithymocyte globulin exposure in CD34+ T-cellâ€“depleted allogeneic hematopoietic cell transplantation. Blood Advances, 2022, 6, 1054-1063.	2.5	12
215	Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes. Biology of Blood and Marrow Transplantation, 2016, 22, 1525-1530.	2.0	11
216	Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusionâ€“Driven Cancer. Cancer Discovery, 2019, 9, 605-616.	7.7	11

#	Article	IF	Citations
217	In Vivo Fluorescent Labeling of Tumor Cells with the HaloTagÂ® Technology. Current Chemical Genomics, 2013, 6, 48-54.	2.0	11
218	Human herpesvirusâ€6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation. Pediatric Transplantation, 2015, 19, 737-744.	0.5	9
219	Translational Strategies for Repotrectinib in Neuroblastoma. Molecular Cancer Therapeutics, 2021, 20, 2189-2197.	1.9	9
220	Using Glow Stick Chemistry for Biological Imaging. Molecular Imaging and Biology, 2014, 16, 478-487.	1.3	8
221	PI3KÎ³/Î´ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature. Molecular Cancer Therapeutics, 2017, 16, 2069-2082.	1.9	8
222	PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo.. Blood, 2005, 106, 247-247.	0.6	8
223	KPT-SINE, a Potent, Small Molecule Inhibitor of CRM1-Dependent Nuclear-Cytoplasmic Shuttling, with Potent Activity Against T-ALL and AML. Blood, 2011, 118, 2622-2622.	0.6	8
224	Inactivation of a Single Copy of Crebbp Selectively Alters Pre-mRNA Processing in Mouse Hematopoietic Stem Cells. PLoS ONE, 2011, 6, e24153.	1.1	7
225	The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-inducible factor-1α in cancer cells, induces cell death, and reduces tumor xenograft growth. Hypoxia (Auckland, N Z), 2016, 4, 15.	1.9	7
226	Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005, 7, 399.	7.7	6
227	Harnessing the power of fireflies and mice for assessing cancer mechanisms. Drug Discovery Today Disease Mechanisms, 2005, 2, 153-158.	0.8	6
228	Quantitative Bioluminescence Imaging of Mouse Tumor Models. Cold Spring Harbor Protocols, 2015, 2015, pdb.prot078261.	0.2	6
229	The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo.. Blood, 2004, 104, 1496-1496.	0.6	6
230	Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor. Pediatric Blood and Cancer, 2022, 69, e29401.	0.8	6
231	Cell of Origin Influences Leukemia Stem Cell Phenotype.. Blood, 2009, 114, 3459-3459.	0.6	6
232	Whole-Genome and Whole-Exome Sequencing in Pediatric Oncology: An Assessment of Parent and Young Adult Patient Knowledge, Attitudes, and Expectations. JCO Precision Oncology, 2018, 2, 1-11.	1.5	5
233	Newer-Generation HSP90 Inhibitors Can Overcome Ibrutinib Resistance and Suppress Proliferation in Human Mantle Cell Lymphoma in Vitro and in Vivo. Blood, 2014, 124, 1686-1686.	0.6	5
234	18F-FDG-PET/CT Imaging of Drug-Induced Metabolic Changes in Genetically Engineered Mouse Lung Cancer Models. Cold Spring Harbor Protocols, 2015, 2015, pdb.prot078246.	0.2	4

#	Article	IF	Citations
235	Summary of COVIDâ€19 clinical practice adjustments across select institutions. Pediatric Blood and Cancer, 2020, 67, e28411.	0.8	4
236	Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusionâ€“associated myeloid neoplasm. Blood Advances, 2022, 6, 1137-1142.	2.5	4
237	HIF2Î± cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation, 2009, 119, 3182-3182.	3.9	4
238	A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2015, 33, 2044-2044.	0.8	4
239	Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. Clinical Cancer Research, 2022, 28, 1614-1627.	3.2	4
240	Global Increase in H3K79 Dimethylation in Murine and Human MLL-AF4 Lymphoblastic Leukemias.. Blood, 2007, 110, 344-344.	0.6	3
241	Life, death and genomic change in perturbed cell cycles. , 1995, , 75-81.		3
242	Anti-tumor immune response after photodynamic therapy. Proceedings of SPIE, 2009, , .	0.8	2
243	Incidence of and Risk Factors for Cytomegalovirus (CMV), Epstein Barr Virus (EBV) and Adenovirus (ADV) Reactivation in Pediatric Recipients Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHCT). Biology of Blood and Marrow Transplantation, 2014, 20, S84-S85.	2.0	2
244	Important Concerns Over SARS-CoV-2 Infection in Children With Cancerâ€”Reply. JAMA Oncology, 2020, 6, 1980.	3.4	2
245	Stepwise Strategic Mitigation Planning in a Pediatric Oncology Center During the COVID-19 Pandemic. Journal of Pediatric Oncology Nursing, 2021, 38, 176-184.	1.5	2
246	Abstract 4622: Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition.. Cancer Research, 2013, 73, 4622-4622.	0.4	2
247	Abstract 4782: Epigenetic resistance to Notch inhibition in T cell acute lymphoblastic leukemia. , 2014, , .		2
248	AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.. Blood, 2004, 104, 551-551.	0.6	2
249	DOT1L and Histone H3 Lysine79 Methylation as a Therapeutic Target in Mixed Lineage Leukemia.. Blood, 2009, 114, 212-212.	0.6	2
250	Selective Inhibition of HDAC1 and HDAC2 Is a Potential Therapeutic Option for B-All. Blood, 2010, 116, 2900-2900.	0.6	2
251	Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM). Blood, 2010, 116, 2997-2997.	0.6	2
252	Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma. Blood, 2011, 118, 2912-2912.	0.6	2

#	Article	IF	Citations
253	Potential Role Of RUNX1 In The Pathogenesis Of Juvenile Myelomonocytic Leukemia (JMML). Blood, 2013, 122, 45-45.	0.6	2
254	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. Blood, 2015, 126, 3252-3252.	0.6	2
255	A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2016, 34, 2077-2077.	0.8	2
256	Preclinical effect of selinexor (KPT-330), a selective inhibitor of nuclear export, in pediatric rhabdoid tumors.. Journal of Clinical Oncology, 2018, 36, 10552-10552.	0.8	2
257	HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias.. Blood, 2006, 108, 734-734.	0.6	2
258	MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenstrol^m's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors. Blood, 2010, 116, 2988-2988.	0.6	2
259	Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition. Blood, 2011, 118, 1405-1405.	0.6	2
260	HSP90 Inhibition Targets JAK2 and Is Highly Effective in CRLF2-Rearranged Acute Lymphoblastic Leukemia. Blood, 2011, 118, 576-576.	0.6	2
261	Targeting MTHFD2 in Acute Myeloid Leukemia. Blood, 2015, 126, 443-443.	0.6	2
262	Children with Gut Acute Graft Versus Host Disease (aGVHD) Following Allogeneic Stem Cell Transplant (AlloHCT) Have an Increased Incidence of Enteric Bacteria Blood Stream Infections (EB-BSI). Biology of Blood and Marrow Transplantation, 2014, 20, S273-S274.	2.0	1
263	High Hematopoietic Transplantation Comorbidity Index Is Not Associated with Increased Transplant Related Mortality: Review of a Large Cohort of Pediatric Patients Undergoing Allogeneic Stem Cell Transplantation Following Busulfan-Based Regimens for Malignant and Non-Malignant Diseases. Biology of Blood and Marrow Transplantation, 2015, 21, S98-S99.	2.0	1
264	Preclinical Magnetic Resonance Imaging in Mouse Cancer Models: TABLE 1.. Cold Spring Harbor Protocols, 2015, 2015, pdb.prot078253.	0.2	1
265	Higher Incidence of Grade III and IV Toxicities in Adolescents Undergoing Allogeneic Hematopoietic Cell Transplantation and Its Impact on Mortality at One Year Post-Transplant: A Retrospective Cohort Study of Pediatric Patients Undergoing Allogeneic Stem. Biology of Blood and Marrow Transplantation, 2015, 21, S206-S207.	2.0	1
266	Abstract 1946: Synergistic effects of the XPO1 inhibitor selinexor with proteasome inhibitors in pediatric high-grade glioma and diffuse intrinsic pontine glioma. , 2017, , .		1
267	Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and Sensitizes Them to Therapy. Blood, 2010, 116, 453-453.	0.6	1
268	Molecular Profiling of High-Risk Pediatric Acute Myeloid Leukemia. Blood, 2016, 128, 5250-5250.	0.6	1
269	Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia.. Blood, 2010, 116, 1042-1042.	0.6	1
270	Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma. Blood, 2011, 118, 2908-2908.	0.6	1

#	Article	IF	Citations
271	CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis. Blood, 2012, 120, 326-326.	0.6	1
272	Novel Fc-Engineered Anti-B Cell Maturation Antigen-Monomethyl Auristatin F Antibody-Drug Conjugate (GSK2857916) Induces Potent and Selective Anti-Multiple Myeloma Activity Via Enhanced Effector Function and Direct Tumor Cell Killing. Blood, 2013, 122, 877-877.	0.6	1
273	Abstract 965: An oncogenic metabolic switch mediates resistance to NOTCH1 inhibition in T-ALL. , 2014, , .		1
274	Evaluating genetic and genomic sequencing knowledge from parents and young adult cancer survivors.. Journal of Clinical Oncology, 2016, 34, 1579-1579.	0.8	1
275	Photodynamic therapy stimulates anti-tumor immunity in a murine model. , 2007, , .		0
276	Sub-Therapeutic Blood Tacrolimus Levels after Conversion from Continuous Intravenous (IV) Infusion to Per Oral (PO) are Associated with Higher Incidence of Acute Graft Versus Host Disease (AGVHD) in Children Following Allogeneic Hematopoietic Cell Transplant (AlloHCT). Biology of Blood and Marrow Transplantation, 2014, 20, S303-S304.	2.0	0
277	Clinical Implementation of Genomic Sequencing in Pediatric Oncology: Identification and Valuation of Resources and Costs Associated with Next-Generation Sequencing. Value in Health, 2014, 17, A645.	0.1	0
278	Human Herpes Virus-6 Viremia is associated with poor clinical outcomes in Children following Allogeneic Hematopoietic Cell Transplantation (AlloHCT)- Statistical Noise or a Real problem?. Biology of Blood and Marrow Transplantation, 2014, 20, S103.	2.0	0
279	The Impact of Subtherapeutic Tacrolimus Levels on the Incidence of Acute Graft-Versus Host-Disease (aGVHD) in Children Following Allogeneic Hematopoietic Cell Transplantation (AlloHCT) â€“ Redefining the Target Range. Biology of Blood and Marrow Transplantation, 2014, 20, S277-S278.	2.0	0
280	Allogeneic Stem Cell Transplantation for Children with Sickle Cell Disease Achieves Quality of Life Similar to Normal Children and Is Cost Effective. Biology of Blood and Marrow Transplantation, 2014, 20, S79.	2.0	0
281	Alemtuzumab Administration in Reduced Toxicity Conditioning (RTC) Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT). What Matters Mostâ€“Timing or Donor Source?. Biology of Blood and Marrow Transplantation, 2015, 21, S209-S210.	2.0	0
282	The Clinical Significance of Non-Tuberculosis Mycobacterium (NTM) Infection in Pediatric Hematopoietic Cell Transplant (HCT) Recipients. Biology of Blood and Marrow Transplantation, 2015, 21, S212.	2.0	0
283	Routine Bone Marrow and CSF Analysis Following Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Children with Leukemia: Lack of Consensus and Questionable Utility. Biology of Blood and Marrow Transplantation, 2015, 21, S231-S232.	2.0	0
284	Predictors of Transplant-Related Mortality at One Year in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Non-Malignant Diseases. Biology of Blood and Marrow Transplantation, 2016, 22, S250-S251.	2.0	0
285	A Single Center Study of Hematopoietic Cell Infusion Related Adverse Events in Children. Biology of Blood and Marrow Transplantation, 2016, 22, S448-S449.	2.0	0
286	Pediatric cancer: case studies illustrate mechanisms to address significant challenges. Journal of Physical Education and Sports Management, 2019, 5, a004788.	0.5	0
287	MLL-AF9 and FLT3 Cooperation during Myeloid Leukemogenesis: Development of a Model for Rapid Testing of New Therapeutics.. Blood, 2005, 106, 1605-1605.	0.6	0
288	Induction of Bim Facilitates Apoptosis in Leukemia Cells Treated with HDAC Inhibitors.. Blood, 2006, 108, 1994-1994.	0.6	0

#	Article	IF	Citations
289	Comprehensive In Vivo Analysis of p300 Hematopoietic Tumor Suppressor Functions.. Blood, 2006, 108, 2553-2553.	0.6	0
290	MLL-AF9 Initiates Leukemia from a Single Committed Hematopoietic Progenitor.. Blood, 2006, 108, 2534-2534.	0.6	0
291	HOXA9 Represses Bim Expression in MLL Rearranged Leukemia: Implications for Drug Therapy.. Blood, 2007, 110, 57-57.	0.6	0
292	The Myocyte Enhancer Factor 2C (MEF2C) Is a Direct Transcriptional Target of HOXA9 and Mediates Leukemia Survival in Human Mixed-Lineage Leukemias.. Blood, 2007, 110, 58-58.	0.6	0
293	Proteasome Inhibition in High-grade Glioma Treatment. Neurosurgery, 2008, 62, 1423.	0.6	0
294	Stapled Peptides: Leveraging the BH3 Î±-Helix to Create a New Class of Drugs to Treat Hematological Malignancies. Blood, 2008, 112, 2929-2929.	0.6	0
295	Activity of Plk Inhibitor BI2536 on Myeloma Cells. Blood, 2008, 112, 2764-2764.	0.6	0
296	In Vivo Imaging Model of Multiple Myeloma and Its Cellular Interaction with the Bone Marrow Microenvironment. Blood, 2008, 112, 647-647.	0.6	0
297	Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.. Blood, 2009, 114, 1722-1722.	0.6	0
298	Abstract 2391: Hsp90-Dependent Regulation of HIF and angiogenic potential in clear-cell renal cell carcinoma. , 2010, , .		0
299	Abstract 5559: Proteomic identification of activated, essential tyrosine kinases in human cancers. , 2010, , .		0
300	Dynamic Regulation of the Level of Hypoxia In the Bone Marrow Regulates Cell Dissemination In Multiple Myeloma. Blood, 2010, 116, 4035-4035.	0.6	0
301	Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3Î± (GSK-3Î±) as a Modulator of Differentiation In Acute Myeloid Leukemia. Blood, 2010, 116, 1000-1000.	0.6	0
302	Demonstration of a Role for Dot1l In MLL-Rearranged Leukemia Using a Conditional Loss of Function Model. Blood, 2010, 116, 62-62.	0.6	0
303	Abstract 2575: Differentiation of NUT midline carcinoma by epigenomic reprogramming. , 2011, , .		0
304	Abstract LB-330: Systematic understanding of tyrosine kinase activation pattern in human cancers. , 2011, , .		0
305	Abstract 2318: BET bromodomain inhibitors for cancer therapy. , 2011, , .		0
306	Abstract 1613: High-throughput tyrosine kinase activity profiling identifies focal adhesion kinase (FAK) as a new target in Ewing sarcoma. , 2011, , .		0

#	Article	IF	Citations
307	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. Journal of Cell Biology, 2011, 194, i8-i8.	2.3	0
308	Hypoxia Promotes Dissemination of Multiple Myeloma Through Acquisition of Endothelial to Mesenchymal Transition (EMT) Features. Blood, 2011, 118, 471-471.	0.6	0
309	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.	0.6	0
310	Intersecting High-Throughput Screens Identifies SERCA As a Target for Modulating NOTCH1 In Hematopoietic Malignancies. Blood, 2011, 118, 555-555.	0.6	0
311	Potentiation of the Effects of Nilotinib by Combination with Plerixafor in a Mouse Model of BCR-ABL-Positive Residual Disease. Blood, 2011, 118, 2737-2737.	0.6	0
312	Abstract LB-351: Identification of new drugs for treatment of renal cell cancer using genomics and the Connectivity Map Database. , 2012, , .		0
313	Abstract 2935: The ATP-competitive mTOR inhibitor Torin2 enhances sensitivity of the ALK F1174L mutation to crizotinib in neuroblastoma. , 2012, , .		0
314	Newer-Generation HSP90 Inhibitors Have Potent Activity Against Human Mantle Cell Lymphoma in Vitro and in Vivo. Blood, 2012, 120, 1651-1651.	0.6	0
315	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1534-1534.	0.6	0
316	Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors.. Blood, 2012, 120, 2455-2455.	0.6	0
317	Aldehyde Dehydrogenase 3a2 (Aldh3a2) Represents a Distinct Metabolic Vulnerability in MLL-AF9 AML Leukemia Initiating Cells. Blood, 2012, 120, 208-208.	0.6	0
318	Novel Inhibitors Of CRM1/XPO1 Nuclear Exporter Exhibit Striking Activity Against AML â€œprimagrafts,â€• Including AML Leukemia Initiating Cells, While Sparing Normal Hematopoietic Cells. Blood, 2013, 122, 3932-3932.	0.6	0
319	Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells. Blood, 2013, 122, 169-169.	0.6	0
320	Targeting Oncogenic Interleukein-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2535-2535.	0.6	0
321	Abstract SY43-03: Screening for triple negative breast cancer vulnerabilities. , 2014, , .		0
322	Abstract 644: Novel anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity via enhanced effector function and direct tumor cell killing. , 2014, , .		0
323	ÂSelective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells. Blood, 2014, 124, 995-995.	0.6	0
324	Abstract B01: Improve MEK/ERK targeting in mutant KRAS lung cancer. , 2014, , .		0

#	Article	IF	Citations
325	Abstract 4445: Selective inhibitor of nuclear exporter CRM1/XPO1, Selinexor (KPT-330), exhibits remarkable activity against AML leukemia-initiating cells while sparing normal hematopoietic cells. , 2015, , .		0
326	Abstract PR01: Precision in Pediatric Sequencing (PIPseq): Clinical implementation of genomic sequencing into pediatric hematology-oncology practice. , 2016, , .		0
327	Targeting MTHFD2 in acute myeloid leukemia. Journal of Cell Biology, 2016, 214, 2141OIA135.	2.3	0
328	Leukemia-Specific Delivery of Mutant NOTCH1 Targeted Therapy. Blood, 2016, 128, 889-889.	0.6	0
329	Abstract 1128: Identification of arginine methyltransferase PRMT5 as a novel therapeutic target in T-cell acute lymphoblastic leukemia. , 2017, , .		0
330	Local drug activation technology to make cytotoxics safer for localized solid tumors.. Journal of Clinical Oncology, 2018, 36, 12082-12082.	0.8	0
331	Abstract 4655: Local drug activation: Making cytotoxics safer for local tumors. , 2018, , .		0
332	Abstract B31: Multiparameter profiling of abscopal effect (AbE) in a pediatric fibrosarcoma with EML4-NTRK3 fusion. , 2018, , .		0
333	Abstract 5105: A plug-and-play infrastructure for scalable bioinformatics operations. , 2019, , .		0
334	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. Blood, 2020, 136, 30-31.	0.6	0